The neurological toll of CAR T cell therapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40513552.
- Also identified by DOI 10.1016/j.cell.2025.04.031.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Understanding acute and long-term adverse events following CAR T cell therapy for cancer remains a crucial area of investigation as CAR T cells become more prominent in the clinic. In this issue of Cell, Geraghty and Acosta-Alvarez et al. investigate the mechanisms underlying cognitive decline in animal models following CAR T cell therapy for hematological, solid, and CNS malignancies.
Medical subject headings
- Immunotherapy, Adoptive
- Receptors, Chimeric Antigen
- Cognitive Dysfunction